Clinical trial
Lenalidomide in Subjects With intermediate2 or High MDS Associated With a…
NCT00424229 · Groupe Francophone des Myelodysplasies, Other · Unknown status
Key facts
| NCT number | NCT00424229 |
|---|---|
| Title | Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] |
| Official title | Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31] |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | LENALIDOMIDE |
| Enrollment | 49 |
| Start date | Oct 1, 2006 |
| Completion | Oct 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Mar 12, 2007 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: